Filing Flows

Filing Flows › Innospec (IOSP) › Q3 2025

Innospec (IOSP) Q3 2025 earnings results (third quarter 2025)

10-Q filed Nov 5, 2025

Innospec (IOSP) reported revenue of $442M for the third quarter 2025 (Q3 2025), -0.3% from a year earlier and +0.5% from the quarter before. Operating margin was 1.3%, net earnings $12.9M (2.9% of revenue).

Revenue$442M
Year over year-0.3%
Quarter over quarter+0.5%
Operating margin1.3%
Net earnings$12.9M

Innospec, Q3 2025: revenue $442M (-0.3% year over year), operating margin 1.3%, net earnings $12.9M, operating cash flow $39.1M. The chart follows the revenue to costs, profit and cash.

Q3 2025AmountQ/QY/Y
Revenue$442M+0.5%-0.3%
Gross profit$117M-5%-6%
Operating profit$5.9M-83%-87%
Net earnings$12.9M-45%-62%
Operating cash flow$39.1M+272%-47%
Free cash flow$24.8M—-62%

What changed

Revenue was $441.9M in Q3 2025, roughly flat year over year and up 1% from the previous quarter.

Gross margin was 26.4%, down 1.6 points from a year earlier. Operating profit was $5.9M, a 1.3% margin (down 8.9 points year over year). Operating expenses grew 41% against flat revenue. The fastest-growing cost line was Other operating costs (+4100%). Net earnings were $12.9M, down 62% year over year. The effective tax rate was -12.4%. Non-operating items added $5.4M, 48% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was $39.1M (down 47% year over year), 308% of net earnings. Non-cash charges added back $12.2M of depreciation and amortization and $900K of share-based compensation. Working capital and other items added $13.3M. Capital expenditures of $14.3M left free cash flow of $24.8M.

Questions

What was Innospec's revenue in the third quarter 2025?

Innospec (IOSP) reported revenue of $442M for the third quarter 2025 (Q3 2025), -0.3% from a year earlier and +0.5% from the quarter before.

Was Innospec profitable in the third quarter 2025?

Operating profit was $5.9M (1.3% of revenue) and net earnings $12.9M.

Open the interactive Sankey →

Source: Innospec 10-Q on SEC EDGAR.